2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-103172
    8-Aminoadenine 28128-33-8 98.34%
    8-Aminoadenine is an adenine receptor ligand, with a Ki of 6.51 μM at the human binding site.
    8-Aminoadenine
  • HY-103324
    Palmitoylisopropylamide 189939-61-5 98%
    Palmitoylisopropylamide is a Palmitoylethanolamide analogue inhibits [3H]-Anandamide metabolism with a pI50 of 4.89.
    Palmitoylisopropylamide
  • HY-103458
    BMS 182874 hydrochloride 1215703-04-0 98%
    BMS 182874 hydrochloride is an orallyactive, highly selective endothelin receptor (ETA receptor) antagonist, with IC50 value of 0.150 μM, Ki of 0.055 μM. BMS 182874 hydrochloride reduces the arterial pressure of Deoxycorticosterone acetate (HY-B1472) induced hypertension model in rats, and can be used for cardiovascular disease research.
    BMS 182874 hydrochloride
  • HY-10450R
    Dapagliflozin (Standard) 461432-26-8
    Dapagliflozin (Standard) is the analytical standard of Dapagliflozin. This product is intended for research and analytical applications. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin induces HIF1 expression and attenuates renal IR injury.
    Dapagliflozin (Standard)
  • HY-10451R
    Canagliflozin (Standard) 842133-18-0
    Canagliflozin (Standard) is the analytical standard of Canagliflozin. This product is intended for research and analytical applications. Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively.
    Canagliflozin (Standard)
  • HY-10512R
    AR-A014418 (Standard) 487021-52-3 98%
    AR-A014418 (Standard) is the analytical standard of AR-A014418. This product is intended for research and analytical applications. AR-A014418 is a potent, selective and ATP-competitive GSK3β inhibitor (IC50=104 nM; Ki=38 nM).
    AR-A014418 (Standard)
  • HY-105217
    Turosteride 137099-09-3 98%
    Turosteride is a selective 5 alpha-reductase inhibitor, with IC50 values of 55 and 53 nM for human and rat prostatic 5 alpha-reductases, respectively. Turosteride can reduce the prostate and seminal vesicle weights.
    Turosteride
  • HY-10532R
    SRT 1720 (Standard) 925434-55-5 98%
    SRT 1720 (Standard) is the analytical standard of SRT 1720. This product is intended for research and analytical applications. SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities for SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively.
    SRT 1720 (Standard)
  • HY-105900
    Ro 22-0654 81741-99-3 98%
    Ro 22-0654 is a potent lipid synthesis inhibitor. Ro 22-0654 inhibits hepatic fatty acid synthesis and has antiobesity effects.
    Ro 22-0654
  • HY-106258
    Atilmotin 533927-56-9 98%
    OHM 11638 (Atilmotin), an analogue of the (1-14) fragment of porcine motilin, is a motilin receptor agonist with a pKd of 8.94 for the motilin receptor. OHM 11638 affects esophageal, lower esophageal sphincter (LES), and gastric motility. OHM 11638 increases LES and gastric pressures, OHM 11638 can be used as prokinetic agents.
    Atilmotin
  • HY-10626R
    T0901317 (Standard) 293754-55-9 98%
    T0901317 (Standard) is the analytical standard of T0901317. This product is intended for research and analytical applications. T0901317 is an orally active and highly selective LXR agonist with an EC50 of 20 nM for LXRα. T0901317 activates FXR with an EC50 of 5 μM. T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively. T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice.
    T0901317 (Standard)
  • HY-106299
    Lilopristone 97747-88-1 98%
    Lilopristone (ZK98734) is a progesterone antagonist with a potential to induce menstruation, inhibit nidation, and terminate pregnancy. Lilopristone blocks progesterone action at the endometrium as well as decreases progesterone bioavailability, and can be utilized in antifertility research.
    Lilopristone
  • HY-10629R
    LXR-623 (Standard) 875787-07-8 98%
    LXR-623 (Standard) is the analytical standard of LXR-623. This product is intended for research and analytical applications. LXR-623 is a brain-penetrant partial LXRα and full LXRβ agonist, with IC50s of 24 nM and 179 nM, respectively.
    LXR-623 (Standard)
  • HY-108922
    Probucol disuccinate 216168-45-5 99.14%
    Probucol Disuccinate is a derivative of Probucol (HY-B0388), a lipid-regulating agent and can reduce LDL-cholesterol levels.
    Probucol disuccinate
  • HY-109060
    Garvagliptin 1601479-87-1 98%
    Garvagliptin (ZYDPLA1) is an orally active, competitive and long acting DPP4 Inhibitor, with an IC50 of 2.99 nM against human recombinant DPP IV. Garvagliptin (ZYDPLA1) exhibits antihyperglycemic effect.
    Garvagliptin
  • HY-10957A
    L-692429 hydrochloride 169188-19-6 98%
    L-692429 (MK-0751) hydrochloride is a benzolactam derivative and a nonpeptidyl growth hormone secretagogue (GHS) agonist. L-692429 hydrochloride binds to G protein-coupled receptor with a Ki of 63 nM.
    L-692429 hydrochloride
  • HY-111074
    DB12055 934017-32-0 98%
    DB12055 (MK-0767 analog) is a covalent SARS-CoV-2 3CL protease inhibitor. DB12055 has the potential for the study of dyslipidemia and diabetes mellitus.
    DB12055
  • HY-111180
    ML262 902502-82-3 98%
    ML-262 is an inhibitor of hepatic lipid droplet formation (IC50=6.4 nM in murine AML-12 cells), which is associated with non-alcoholic fatty liver disease.1 ML-262 does not induce cytotoxicity (up to 33 μM) or inhibit fatty acid uptake (up to 50 μM).
    ML262
  • HY-111232
    GSK894281 874958-63-1 98%
    GSK894281 is an orally active and highly potent ghrelin receptor full agonist with a pEC50 of <4.9 at the human motilin receptor. GSK894281 effectively enters the CNS. GSK894281 has the potential for constipation or to assist in emptying the colon prior to colonoscopy or colon surgery research.
    GSK894281
  • HY-111293
    Arachidonamide 85146-53-8 98%
    Arachidonamide is substrate of anandamide amidohydrolase.
    Arachidonamide
Cat. No. Product Name / Synonyms Application Reactivity